342
Views
41
CrossRef citations to date
0
Altmetric
Review

Management of pancreatogenic diabetes: challenges and solutions

Pages 311-315 | Published online: 25 Aug 2016

Abstract

Pancreatogenic diabetes is an underdiagnosed form of secondary diabetes that is lacking official management guidelines. This paper reviews the recommended management strategies with additional data on the promising novel drugs.

Introduction

Pancreatogenic diabetes is a form of secondary diabetes, classified by the American Diabetes Association (ADA) and the World Health Organization as type 3c diabetes mellitus (T3cDM).Citation1,Citation2 It refers to diabetes due to diseases of the exocrine pancreas: pancreatitis (acute, relapsing, or chronic pancreatitis of any etiology), pancreatectomy/trauma, neoplasia, cystic fibrosis, hemochromatosis, and fibrocalculous pancreatopathy.Citation3 With the exception of cancer, damage to the pancreas must be extensive enough for diabetes to occur.Citation1,Citation2 Rather scarce data on T3cDM suggest that most cases result from chronic pancreatitis, as this condition was identified as the underlying disease in 78.5% of all patients with T3cDM.Citation4

In Western populations, T3cDM is estimated to occur in 5%–10% of all diabetic patients, mostly due to chronic pancreatitis.Citation4Citation6 True prevalence of T3cDM is unknown – data are scarce, mostly due to challenges with accurate diabetes classification in clinical practice.Citation4,Citation7Citation9 Many T3cDM patients are initially misclassified due to underrecognized contribution of pancreatic disease to the development of diabetes. In order to improve diagnosis, diagnostic criteria for T3cDM have been proposed by Ewald and Bretzel which include 1) the presence of pancreatic exocrine insufficiency, 2) evidence of pathological pancreatic imaging, and 3) the absence of type 1 diabetes mellitus (T1DM)-associated autoantibodies.Citation6 They may be further supported by additional minor criteria, such as an absent pancreatic polypeptide (PP) response to mixed-nutrient ingestion.Citation6 These criteria may be more reliably applied at the presentation of diabetes due to a degree of overlap in established insulin deficiency (related to pancreatic atrophy and exocrine insufficiency). It is also worth noting that type 2 diabetes mellitus (T2DM) is common enough in the general population to accidentally coexist with exocrine pancreatic disease.Citation9,Citation10

Despite the limited data, T3cDM patients appear to share a similar risk for the micro- and macro-vascular complications of diabetes as in T1DM and T2DM.Citation11,Citation12 Therefore, they should be equally monitored according to guidelines for patients with T1DM and T2DM.Citation13,Citation14 Unlike T1DM and T2DM that increase the risk of pancreatic cancer, T3cDM is an effect and therefore a harbinger of pancreatic cancer in at least 30% of patients.Citation15

Pathophysiology

Although classified as a unified group of secondary diabetes, the pathophysiological background of T3cDM differs. Damage to the pancreas disrupts the complex interplay of nutrient digestion, absorption, and utilization at different levels. Endocrine dysfunction represents deficiency of insulin, glucagon, PP, and incretin hormones. Typically, some degree of exocrine dysfunction with maldigestion and malabsorption of nutrients coexists.Citation5,Citation9,Citation16

The pathogenesis of T3cDM is ultimately due to decreased insulin secretion; data on hepatic and peripheral tissue insulin sensitivity differ.Citation9,Citation17Citation19 Impaired counterregulation due to deficient glucagon secretion, blunted catecholamine response, and impaired activation of hepatic gluconeogenesis result in glycemic instability with hypoglycemic reactions.Citation20

Management

Currently, there are no specific guidelines to manage T3cDM as a separate entity. Only two documents exist that can serve as recommendations for T3cDM diabetes management.Citation13,Citation14 For chronic pancreatitis, recommendations result from a consensus conference of gastroenterologists, endocrinologists, and surgeons with clinical and research expertise in the management of chronic pancreatitis and its complications.Citation14 For cystic fibrosis patients, a position statement from the ADA is part of clinical care guidelines for cystic fibrosis-related diabetes.Citation13

Glycemic control

The current ADA standard of diabetes care does not set specific glycemic targets for T3cDM.Citation2 Therefore, as with T1DM and T2DM, the primary target is to achieve and maintain the HbA1c <7% in order to minimize the risk of chronic complications.Citation13,Citation14 Keeping in mind the term “brittle diabetes”, it is important to avoid hypoglycemia – blood glucose levels should be slightly above the normal to improve the quality of life.Citation5,Citation8,Citation20,Citation21

Lifestyle modifications

Attempts to reduce the toxic and modifiable contributors to chronic pancreatitis such as abstaining from alcohol and smoking cessation are highly recommended as both exacerbate progression of underlying pancreatic inflammation and fibrosis and contribute to pain. Abstaining from alcohol is also helpful for diabetes management, since alcohol acutely inhibits hepatic glucose production and can cause hypoglycemia, especially in the setting of insulin therapy.Citation9 Due to its vital role in overall health, the guidelines for cystic fibrosis-related T3cDM also recommend moderate aerobic exercise for at least 150 minutes per week.Citation13

Nutrition

In chronic pancreatitis-associated diabetes, preventing/treating malnutrition, controlling symptoms of steatorrhea, and minimizing meal-induced hyperglycemia are the primary goals of medical nutritional therapy.Citation14 Patients should be encouraged to eat meals that are rich in soluble fiber and low in fat. In case of pancreatic exocrine insufficiency (of any degree), concomitant oral enzyme replacement therapy should be prescribed. Oral pancreatic enzyme replacement is particularly important for fat digestion and nutrients absorption. It helps to control symptoms of steatorrhea, protect against fat-soluble vitamin deficiency, and is important for maintaining incretin hormone secretion and thus improving glucose tolerance.Citation5,Citation9,Citation22Citation24 Vitamin D deficiency is frequently present in chronic pancreatitis, even in exocrine-sufficient patients.Citation25 Osteoporosis frequency in these patients is 34%, which is three times higher in comparison to controls.Citation26

In cystic fibrosis-related T3cDM, similarly, good nutritional status and normal blood glucose levels are the primary goals. Patients are encouraged toward a well-balanced diet with no restriction in caloric intake, no fat, or carbohydrate restriction – all due to increased resting energy expenditure and malabsorption. Fat-soluble vitamins should be routinely supplemented. In contrast to other types of diabetes, there should be no salt and protein restriction in cystic fibrosis-related T3cDM, even in the setting of concomitant arterial hypertension or microvascular complications.Citation13

Antihyperglycemic agents

There are no current common guidelines for T3cDM treatment. Although T3cDM represents a unified group of secondary diabetes, the pathophysiological background differs. Therefore, different treatment options should be taken into account and tailored individually.

In chronic pancreatitis-associated diabetes with mild hyperglycemia (HbA1c <8%), oral hypoglycemic agents may be appropriate.Citation14 Metformin, an insulin sensitizer, should be considered in case of concomitant insulin resistance due to the theoretical rationale in reducing risk of pancreatic cancer.Citation5,Citation21,Citation27Citation29 On the other hand, it is often badly tolerated due to gastrointestinal adverse effects and weight loss, which are undesired in chronic pancreatitis.Citation9,Citation14 Another group of insulin sensitizers, thiazolidinediones, are generally avoided due to their relation to fluid retention, congestive heart failure, and (particularly undesired) increased risk of fractures.Citation14,Citation30 Insulin secretagogues (sulfonylureas and glinides) increase the risk of malignancy and can cause hypoglycemia.Citation5,Citation27,Citation31 If considered, short-acting agents are preferred, especially when meal ingestion is inconsistent.Citation9,Citation14 Oral hypoglycemic agents are not recommended in cystic fibrosis-related T3cDM, as they are not as effective as insulin in improving nutritional and metabolic outcomes.Citation13

Chronic pancreatitis patients with T3cDM not requiring insulin show a parallel to T2DM regarding the pathophysiology of the incretin defect and might benefit from incretin-based antidiabetic therapy.Citation23 Incretin-based therapies (eg, GLP-1 analogs and DPP-IV inhibitors) enhance insulin secretion, but their use in these patients has been precluded due to association with cases of drug-induced pancreatitis.Citation9,Citation32,Citation33 Also, GLP-1 analogs have been shown to reduce appetite and food intake leading to weight loss, which is not desired in these patients.Citation34 Therefore, their use is not recommended until more data become available.Citation9,Citation14

There are also no current data available on use of potential sodium–glucose cotransporter 2 inhibitors in T3cDM patients. Although they seem efficient in T2DM management and do not cause hypoglycemia, their main side effect is weight loss, which is unwanted in T3cDM.Citation35,Citation36

Insulin increases the risk of malignancy.Citation5,Citation27,Citation31 But for most T3cDM patients, the principal endocrine defect is insulin deficiency, and therefore, insulin therapy is the preferred treatment.Citation9 Insulin is the treatment of choice in cystic fibrosis-related T3cDM.Citation13 In this disease, insulin use is reported to improve outcomes in lung function, pulmonary exacerbation rates, nutritional status, blood glucose control, and decreased mortality.Citation37Citation42 Insulin can also be used for other forms of T3cDM, especially for correcting hyperglycemia in chronic acutely ill or hospitalized patients and in severely malnourished patients (to whom the anabolic effects of insulin are particularly beneficial).Citation9,Citation14 In advanced T3cDM, multidose basal–bolus insulin dosing regimens should follow guidelines for the treatment of T1DM, and include carbohydrate counting for flexible prandial coverage and consideration of continuous subcutaneous insulin infusion or “pump” delivery.Citation9,Citation13,Citation14 However, in all insulin-based regimens, attention should be drawn to possible hypoglycemias.Citation36 Deficient counterregulatory glucagon secretion from islet α-cells, combined with blunted catecholamine response and impaired activation of hepatic gluconeogenesis, predisposes to hypoglycemia, which is often unpredictable in replacement doses of insulin.Citation9,Citation20,Citation43

Total pancreatectomy with islet autotransplantation

It is a surgical method used in selected patients to treat severe complications (pain) of recurrent acute and chronic pancreatitis or in those with very high risk of pancreatic cancer while reducing the risk of severe diabetes mellitus.Citation44 It does not serve as a prevention or treatment strategy of T3cDM per se, although it increases chances of good glycemic control.Citation9 The selection criteria of patients are limitative, and therefore, the number of beneficiaries is very low.Citation45

Promising novel drugs

PP has shown great promise as an antidiabetic drug for treatment of T3cDM secondary to chronic pancreatitis.Citation46Citation50 It increases the expression of insulin receptors in the liver, thus enabling effective utilization of circulating insulin.Citation49Citation52 It improves insulin sensitivity and decreases insulin requirements in T3cDM patients.Citation49,Citation52 A novel formulation of PP in stabilized phospholipid micelles has been shown to overcome the obstacle of PP’s short biological half-life and demonstrate significant antidiabetic activity in a rodent model of pancreatogenic diabetes.Citation53

Conclusion

There are no current common guidelines for T3cDM management. Management strategies balance on the edge between optimal glycemic control to minimize the risk of chronic complications and avoiding hypoglycemic reactions but at the same time address malnutrition and disturbing gastrointestinal symptoms of steatorrhea to improve the quality of life.

Disclosure

The author has received lecture fees from Sanofi Aventis, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim. The author reports no other conflicts of interest in this work.

References

  • World Health Organization Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus Geneva World Health Organization 1999 [cited May 5, 2016]. Available from: http://apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf Accessed May 5, 2016
  • American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 2014 37 Suppl 1 S81 S90 24357215
  • American Diabetes Association Standards of medical care in diabetes 2016 Diabetes Care 2016 39 Suppl 1 S1 S112 26696671
  • Ewald N Kaufmann C Raspe A Kloer HU Bretzel RG Hardt PD Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c) Diabetes Metab Res Rev 2012 28 4 338 342 22121010
  • Cui Y Andersen DK Pancreatogenic diabetes: special considerations for management Pancreatology 2011 11 3 279 294 21757968
  • Ewald N Bretzel RG Diabetes mellitus secondary to pancreatic diseases (Type 3c) - are we neglecting an important disease? Eur J Intern Med 2013 24 3 203 206 23375619
  • Hardt PD Brendel MD Kloer HU Bretzel RG Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed? Diabetes Care 2008 31 Suppl 2 S165 S169 18227480
  • Andersen DK The practical importance of recognizing pancreatogenic or type 3c diabetes Diabetes Metab Res Rev 2012 28 4 326 328 22279014
  • Gudipaty L Rickels MR Pancreatogenic (type 3c) diabetes Pancreapedia: Exocrine Pancreas Knowledge Base 2015 [cited May 5, 2016]. Available from: http://www.pancreapedia.org/sites/www.pancreapedia.org/files/DOI%20V3.%20formatted%20Type%203c%20DM%20chapter%208-13-15.pdf Accessed May 5, 2016
  • Balzano G Dugnani E Pasquale V Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients Acta Diabetol 2014 51 5 801 811 24974302
  • Couet C Genton P Pointel JP The prevalence of retinopathy is similar in diabetes mellitus secondary to chronic pancreatitis with or without pancreatectomy and in idiopathic diabetes mellitus Diabetes Care 1985 8 4 323 328 4042797
  • Wang W Guo Y Liao ZA Occurrence of and risk factors for diabetes mellitus in Chinese patients with chronic pancreatitis Pancreas 2011 40 2 206 212 21404458
  • Moran A Brunzell C Cohen RC Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society Diabetes Care 2010 33 12 2697 2708 21115772
  • Rickels MR Bellin M Toledo FGS Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012 Pancreatology 2013 13 4 336 342 23890130
  • Magruder JT Elahi D Andersen DK Diabetes and pancreatic cancer: chicken or egg? Pancreas 2011 40 3 339 351 21412116
  • Whitcomb D Chronic pancreatitis, type 3c diabetes, and pancreatic cancer risk JOP 2014 15 5 2773
  • Yasuda H Harano Y Ohgaku S Insulin sensitivity in pancreatitis, liver-diseases, steroid treatment and hyperthyroidism assessed by glucose, insulin and somatostatin infusion Horm Metab Res 1984 16 1 3 6 6141989
  • Yki-Jarvinen H Kiviluoto T Taskinen MR Insulin resistance is a prominent feature of patients with pancreatogenic diabetes Metabolism 1986 35 8 718 727 3736412
  • Nathan JD Zdankiewicz PD Wang J Impaired hepatocyte glucose transport protein (GLUT2) internalization in chronic pancreatitis Pancreas 2001 22 2 172 178 11249072
  • Tiengo A Vigili de Kreutzenberg S Del Prato S Diabetes in pancreatitis, pancreatectomy and other pancreatic diseases Ghigo E Porta M Diabetes Secondary to Endocrine and Pancreatic Disorders Front Diabetes 22 Basel Karger 2014 119 143
  • Cui Y Andersen DK Diabetes and pancreatic cancer Endocr Relat Cancer 2012 19 5 F9 F26 22843556
  • Ebert R Creutzfeldt W Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution Diabetologia 1980 19 3 198 204 6997121
  • Knop FK Incretin hormones and beta cell function in chronic pancreatitis Dan Med Bull 2010 57 7 B4163 20591345
  • Knop FK Vilsboll T Larsen S Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution Am J Physiol Endocrinol Metab 2007 292 1 E324 E330 16954337
  • Sikkens ECM Cahen DL Koch AD The prevalence of fat-soluble vitamin deficiencies and a decreased bone mass in patients with chronic pancreatitis Pancreatology 2013 13 3 238 242 23719594
  • Duggan SN O’Sullivan M Hamilton S Feehan SM Ridgway PF Conlon KC Patients with chronic pancreatitis are at increased risk for osteoporosis Pancreas 2012 41 7 1119 1124 22836855
  • Li D Yeung SC Hassan MM Konopleva M Abbruzzese JL Anti-diabetic therapies affect risk of pancreatic cancer Gastroenterology 2009 137 2 482 488 19375425
  • Libby G Donnelly LA Donnan PT Alessi DR Morris AD Evans JM New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes Diabetes Care 2009 32 9 1620 1625 19564453
  • Sadeghi N Abbruzzese JL Yeung SC Hassan M Li D Metformin use is associated with better survival of diabetic patients with pancreatic cancer Clin Cancer Res 2012 18 10 2905 2912 22465831
  • Kung J Henry RR Thiazolidinedione safety Expert Opinion Drug Saf 2012 11 4 565 579
  • Bowker SL Majumdar SR Veugelers P Johnson JA Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 2006 29 2 254 258 16443869
  • Elashoff M Matveyenko AV Gier B Elashoff R Butler PC Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies Gastroenterology 2011 141 1 150 156 21334333
  • Iyer SN Tanenberg RJ Mendez CE Lee West R Drake AJIII Pancreatitis associated with incretin-based therapies Diabetes Care 2013 36 4 E49 23520376
  • Larsen PJ Mechanisms behind GLP-1 induced weight loss Br J Diabetes Vasc Dis 2008 8 Suppl 2 S34 S41
  • Cefalu WT Riddle MC SGLT2 inhibitors: the latest “new kids on the block”! Diabetes Care 2015 38 3 352 354 25715412
  • Meier JJ Giese A Diabetes associated with pancreatic diseases Curr Opin Gastroenterol 2015 31 5 400 406 26125315
  • Rolon MA Benali K Munck A Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy Acta Paediatr 2001 90 8 860 867 11529531
  • Lanng S Thorsteinsson B Nerup J Koch C Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections Acta Paediatr 1994 83 8 849 853 7981562
  • Mozzillo E Franzese A Valerio G One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements Pediatr Diabetes 2009 10 3 162 167 19207231
  • Mohan K Israel KL Miller H Grainger R Ledson MJ Walshaw MJ Long-term effect of insulin treatment in cystic fibrosis related diabetes Respiration 2008 76 2 181 186 17960051
  • Hardin DS Rice J Rice M Rosenblatt R Use of the insulin pump to treat cystic fibrosis-related diabetes J Cyst Fibros 2009 8 3 174 178 19162566
  • Moran A Dunitz J Nathan B Saeed A Holme B Thomas W Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality Diabetes Care 2009 32 9 1626 1631 19542209
  • Larsen S Hilsted J Tronier B Worning H Pancreatic hormone secretion in chronic pancreatitis without residual beta-cell function Acta Endocrinol (Copenh) 1988 118 3 357 364 2899369
  • Bellin MD Freeman ML Gelrud A Total pancreatectomy and islet autotransplantation in chronic pancreatitis: Recommendations from PancreasFest Pancreatology 2014 14 1 27 35 24555976
  • Grigore C Sarbu V Simion S Simion I Poteca T Nedelea S Pancreatogenic diabetes patient selection for pancreatic islet transplantation J Med Life 2010 3 1 84 89 20302203
  • Sun YS Brunicardi FC Druck P Reversal of abnormal glucose metabolism in chronic pancreatitis by administration of pancreatic polypeptide Am J Surg 1986 151 1 130 140 3946744
  • Brunicardi FC Chaiken RL Ryan AS Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis J Clin Endocrinol Metab 1996 81 10 3566 3572 8855802
  • Maeda H Hanazaki K Pancreatogenic diabetes after pancreatic resection Pancreatology 2011 11 2 268 276 21734430
  • Rabiee A Galiatsatos P Salas-Carrillo R Thompson MJ Andersen DK Elahi D Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy J Diabetes Sci Technol 2011 5 6 1521 1528 22226275
  • Hennig R Kekis PB Friess H Adrian TE Buchler MW Pancreatic polypeptide in pancreatitis Peptides 2002 23 2 331 338 11825647
  • Andersen DK Mechanisms and emerging treatments of the metabolic complications of chronic pancreatitis Pancreas 2007 35 1 1 15 17575539
  • Andersen DK Andren-Sandberg Å Duell EJ Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop Pancreas 2013 42 8 1227 1237 24152948
  • Banerjee A Onyuksel H A novel peptide nanomedicine for treatment of pancreatogenic diabetes Nanomedicine 2013 9 6 722 728 23347897